Although venetoclax demonstrated low single agent effects in clinical trials with B cell lymphomas, combination regimen (such as venetoclax and ibrutinib in refractory MCL or venetoclax and R-CHOP in DLBCL) suggest promising efficacy and good tolerability54,55. The gene discussed is DDIT3; the disease is B-cell non-Hodgkin lymphoma.